Navigation Links
Cerecor Acquires Rights to Merck COMT Inhibitors
Date:3/20/2013

BALTIMORE, March 20, 2013 /PRNewswire/ -- Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights to develop, register and commercialize agents that inhibit catechol-O-methyltransferase inhibitors ("COMT inhibitors"), previously discovered and owned by Merck, known as MSD outside the United States and Canada. 

(Logo: http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

COMT is an enzyme that breaks down dopamine, a neurotransmitter that plays a key role in higher brain functions such as motivation, cognition and emotion. Drugs that inhibit COMT have been used to treat patients with Parkinson's disease; however, they have poor brain penetration and limited safety and tolerability.   COMT inhibition also has broad potential applicability in other CNS diseases, such as addictive behaviors and schizophrenia, by specifically increasing dopamine levels in areas of the brain affected by these conditions.  While the development of schizophrenia drugs to date has focused on reducing psychosis, improvement in functional outcome has been largely unattainable because current drugs do not have clinically significant impact on the "negative symptoms" and cognitive impairment of the disease.  Drugs that inhibit COMT improve working memory and other measures of cognitive function in animals and in clinical studies (normal subjects and in schizophrenics). 

"Merck has developed an innovative COMT platform that has addressed the toxicity associated with existing COMT drugs.  By accessing this platform, Cerecor broadens its cognition pipeline, which also includes DAAO inhibitors.  This enhances our leadership in neuropsychiatric drug development," stated Dr. Reza Mazhari , Cerecor's VP of Drug Discovery and Development. 

Under the terms of the agreement, Cerecor will evaluate more than 2,000 molecules and select lead candidates for clinical development. Consideration includes milestone payments and royalties consistent with other preclinical licenses in neuroscience. Cerecor anticipates completing the technology transfer activities in 2013. 

"Adding COMT inhibitors to our drug development portfolio enhances our mission. Cerecor continues to focus on targets or technologies that have demonstrated human proof of concept, and for which biomarkers could be used to steer early clinical development. We are delighted that Merck has chosen Cerecor to help realize the value of such an innovative body of work as contained within their COMT patent portfolio," added Dr. Blake Paterson , Cerecor's co-founder and CEO.

"Cerecor's approach to the development of safe and effective therapies, combined with its experienced management team, makes them ideally suited to help advance this platform targeted for the treatment of CNS diseases," said Dr. Richard Hargreaves , Vice President, Worldwide Head of Basic Research, Neuroscience, Merck Research Laboratories.

About Cerecor

Cerecor Inc is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and co-founded in April 2011 by Drs. Solomon Snyder , Barbara Slusher , Blake Paterson and Mr. Isaac Blech . Cerecor is focused on translational medicine – the accelerated transfer of technology from the laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.

Contact:
Karen Krumeich   
+1-410-522-8707


'/>"/>
SOURCE Cerecor Inc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerecor Announces Initiation of CLIN01-002-A
2. Dr. Magnus Persson Joins Cerecors Board of Directors
3. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
4. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
5. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
6. PLZ Aeroscience Acquires Assured Packaging
7. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
8. PneumRx, Inc. Acquires Key Assets From Broncus
9. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
10. Frazier Healthcare Acquires U.S. Commercial Pharmaceutical Packaging Operations from Catalent Pharma Solutions
11. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):